Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
Open Access
- 6 November 2013
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 28 (3) , 621-628
Abstract
The nucleoside analog azacitidine (AZA) is used in the treatment of myelodysplastic syndromes (MDS), but 30–40% of patients fail to respond or relapse after treatment. Hence, to identify new molecular alterations that allow for identification of patients unlikely to respond to AZA could impact the utility of this therapy. We determined the expression levels of genes involved in AZA metabolism: UCK1, UCK2, DCK, hENT1, RRM1 and RRM2 using quantitative PCR in samples from 57 patients with MDS who received AZA. Lower expression of UCK1 was seen in patients without a response to AZA (median 0.2 vs 0.49 for patients with response to AZA, P=0.07). This difference in UCK1 expression was not influenced by aberrant methylation of the UCK1 promoter. In addition, the seven polymorphic loci found in the coding sequence were not associated with UCK1 gene expression nor AZA response. Silencing of UCK1 by siRNA leads to blunted response to AZA in vitro. The univariate analysis revealed that patients expressing lower than median levels of UCK1 had a shorter overall survival (P=0.049). Our results suggest that expression level of UCK1 is correlated with clinical outcome and may influence the clinical response to AZA treatment in patients with MDS.Keywords
This publication has 48 references indexed in Scilit:
- RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemiaBlood, 2012
- Mechanisms of Resistance to Decitabine in the Myelodysplastic SyndromePLOS ONE, 2011
- A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell LinesPLOS ONE, 2010
- DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2010
- Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDSProceedings of the National Academy of Sciences, 2009
- Mutation inTET2in Myeloid CancersNew England Journal of Medicine, 2009
- Aberrant DNA methylation is a dominant mechanism in MDS progression to AMLBlood, 2009
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- Cell entry and export of nucleoside analoguesVirus Research, 2005
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003